News

In a Phase 3 clinical trial, Opsumit (macitentan) did not meet the study’s primary goal — improved exercise capacity — in patients with pulmonary arterial hypertension (PAH) due to Eisenmenger syndrome, Actelion, the drug’s manufacturer, announced. Study results, however, will take time to interpret due to a “persistent placebo effect,”…

In a moderately sized group of patients with pulmonary hypertension (PH), nonsustained ventricular tachycardia (nsVT) occurred more often than previously reported, researchers said, and patients with PH group 1 seemed to be more at risk. Nonsustained ventricular tachycardia is an abnormally rapid ventricular rhythm, usually greater than 100 beats per…

A case report of a pulmonary arterial hypertension (PAH) patient who used an implanted hemodynamic monitor illustrates that improvements in pulmonary hemodynamics and right ventricle afterload with a “simple therapy” like oral iron supplements are both possible and measurable. The study, “Hemodynamic response to treatment of iron deficiency anemia in pulmonary arterial hypertension:…

PhaseBio Pharmaceuticals announced the closing of $14.7 million in a financing mechanism called convertible notes that will help it  advance the clinical development of PB1046, its lead candidate to treat rare diseases of the heart and lungs, including pulmonary arterial hypertension (PAH). PB1046 is a vasoactive intestinal peptide (VIP) receptor agonist, being…

Scientists at Imperial College London have designed software that creates virtual 3-D versions of patients’ heart motion, helping doctors to determine likely outcomes in patients with pulmonary hypertension (PH) with greater accuracy, and possibly improve their treatment. The technology uses cardiac magnetic resonance imaging (MRI), blood tests, and other clinical observations, according to…

Pulmonary hypertension is a common outcome of bronchopulmonary dysplasia (BPD) in premature infants, with one in every or five pre-term babies with BPD going on to develop PH, a study reports. The study, “Bronchopulmonary dysplasia and pulmonary hypertension: a meta-analysis,” showed that the odds ratio (the likelihood) of developing…

Women with high-risk congenital heart disease can safely become pregnant and give birth if they are carefully monitored and managed by doctors, according to a new scientific statement by the American Heart Association. “Management Of Pregnancy In Patients With Complex Congenital Heart Disease: A Scientific Statement For Healthcare Professionals…

Almost one-fourth of pulmonary arterial hypertension (PAH) patients in a small recent study had pulmonary artery aneurysm (PAA), a condition marked by serious heart complications. Its researchers recommend that PAH patients with signs of heart failure be screened for aneurysms. The study, “Cardiac Dysfunction Of Pulmonary Artery Aneurysm In…

A recent study showed that patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) responded well to a combination therapy with ambrisentan and tadalafil, with a lower incidence of clinical failure when compared to therapy with either drug alone. The response, however, was not as impressive when compared to initial use of the…

SteadyMed Therapeutics recently reported its strategic goals and priorities for 2017, including plans to file a New Drug Application (NDA) to market Trevyent in the U.S., the company’s lead candidate to treat pulmonary arterial hypertension (PAH). Trevyent is based on treprostinil, the only parenteral therapy for PAH approved by the…

Vivus has acquired the global exclusive rights from Selten Pharma to develop and commercialize tacrolimus and ascomycin, two investigational treatments for pulmonary arterial hypertension (PAH) and other vascular diseases. Vivus, a biopharmaceutical company based on Campbell, California, acquired Selten’s licence to a series of patents owned by the Board of…

Researchers have identified a disease mechanism that could be targeted to develop treatments for pulmonary arterial hypertension (PAH). In a rat model of PAH, a compound that reduces oxidative stress lowered pulmonary pressure and prevented remodeling of lung blood vessels. Oxidative stress is a major contributor to the events leading…